CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...